[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipoproteina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipoproteina":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,71,112,139,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641216","phase-3-a-study-to-see-if-lepodisiran-can-reduce-plaque-in-coronary-arteries-of-adults-with-elevated-lpa-who-have-had-heart-events-or-are-at-high-risk-100641216",false,"NCT07613294","A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event","ACCLAIM-CTA","Inclusion Criteria:\n\n* Have an Lp(a) ≥175 nmol\u002FL\n* Have established cardiovascular (CV) disease or are at risk for a first CV event\n* Have angiographic evidence of coronary artery disease on screening CCTA\n* If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks\n\nExclusion Criteria:\n\n* Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening\n* Have moderate to severe renal dysfunction\n* Have severe heart failure\n* Have a history of coronary artery bypass graft surgery (CABG)\n* Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention\n* Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)\n* Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical\u002Ftechnical factors","ALL","45 Years","80 Years",{"count":21,"type":22},252,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).\n\nParticipation will last about 120 weeks.",[28,29,30],"Atherosclerosis","Cardiovascular Diseases","Lipoprotein(a)",[32,33],"CCTA","Coronary plaque burden","RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2026-06-02",{"date":42,"type":22},"2029-04",{"name":44,"class":45},"Eli Lilly and Company","INDUSTRY",59,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100640331","phase-2-a-clinical-trial-of-mk-7262-and-enlicitide-in-participants-with-high-lipoproteina-mk-7262-004-100640331","NCT07614984","A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has Lp(a) ≥ 150 nmol\u002FL\n* Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH\n* Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization\n* Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)\n* Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection\n* Has a history of nephrotic syndrome\n* Has severe renal insufficiency\n* Has received certain therapies in the prohibited timeframe as specified in the protocol\n* Has active or chronic hepatobiliary or hepatic disease\n* Has poorly controlled Type 1 or Type 2 diabetes","18 Years",{"count":56,"type":22},750,[58],"PHASE2","Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C).\n\nThe goals of this trial are to evaluate:\n\n* if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood\n* if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood\n* the safety and tolerability of taking MK-7262 and enlicitide alone and together",[30],"NOT_YET_RECRUITING","2026-05-22",{"date":64,"type":38},"2026-05-29",{"date":66,"type":22},"2026-07-07",{"date":68,"type":22},"2027-10-12",{"name":70,"class":45},"Merck Sharp & Dohme LLC",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100637404","ai-assisted-ct-for-risk-stratification-in-coronary-artery-disease-action-100637404","NCT07577609","AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)","Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes","ACTION","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing clinically indicated cardiac CT\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)\n* Contraindications to iodinated contrast agents or CT imaging",true,{"count":81,"type":22},10000,"5 Years","OBSERVATIONAL","The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.\n\nThe main questions it aims to answer are:\n\n* Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?\n* How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.\n\nParticipants will:\n\n* Provide informed consent and medical history\u002Fdemographic information\n* Undergo blood sampling for cardiovascular and metabolic biomarkers\n* Have a resting ECG performed\n* Complete a detailed lifestyle and health questionnaire\n* Receive a non-invasive cardiac CT scan interpreted by an expert\n* Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality\n* Be referred for further clinical evaluation if clinically indicated ",[86,87,88,89,30,90,91],"Coronary Artery Disease (CAD)","Computed Tomography Angiography","Biomarkers","AI (Artificial Intelligence)","Atheroscleroses, Coronary","Myocardial Ischemia",[93,94,95,96,97,98,99,100],"AI-assisted cardiac CT","Coronary CT angiography (CCTA)","Cardiovascular risk stratification","Coronary plaque characterization","High-risk plaque","Machine learning","CT-FFR (fractional flow reserve)","Coronary calcium scoring","2026-05-05",{"date":103,"type":38},"2026-05-11",{"date":105,"type":38},"2022-12-21",{"date":107,"type":22},"2032-12-21",{"name":109,"class":110},"University of Galway","OTHER",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":111},"100622345","electronic-letters-to-improve-patient-activation-in-ihd-the-nudge-ihd-trial-100622345","NCT07382414","Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial","NUDGE-IHD: A Nationwide Pragmatic Randomized Trial of Electronic Nudges to Increase Patient Activation to Support Risk-factor Control in Ischemic Heart Disease","NUDGE-IHD","Inclusion criteria\n\n* Alive on identification date\n* Diagnosis of IHD defined as either an A or B diagnosis code of I20-I25 in the Danish National Patient Register first registered \\> 6 months prior to identification date\n* Latest available LDL-C is over 1.4 mmol\u002Fl measured up to 3 years prior to the identification date, defined using NPU codes NPU01568, NPU10171 or DNK35308 from the Danish National Laboratory Register\n* Age \\>= 18 years and \\\u003C= 85 on identification date\n\nExclusion criteria\n\n* Nursing home residents\n* Exemption from and thus not access to Digital Post","85 Years",{"count":122,"type":22},100000,[124],"NA","The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) \\[Lp(a)\\] will also be randomized to receive an additional information letter.\n\nThe main questions the study aims to answer are:\n\n* Does sending an electronic letter about elevated LDL cholesterol increase the proportion of patients who have at least one LDL-cholesterol test within 6 months?\n* Among patients with ischemic heart disease and elevated Lp(a), does receiving an information letter about Lp(a) increase patient activation, reflected by cardiometabolic risk-factor monitoring?\n\nBecause this is a randomized trial, researchers will compare people who receive the electronic letter(s) with people who do not receive any letter to determine whether the letters encourage patients to take action, such as obtaining laboratory tests or contacting their doctor.\n\nParticipants will:\n\n* Receive an electronic letter through Denmark's national digital mailbox system (Digital Post) or receive no letter, depending on random assignment.\n* Continue their usual health care, with no additional visits, treatments, or procedures required for the study.\n* Have all study information collected from existing Danish nationwide health registries.",[127,128,30,129],"Coronary Artery Disease","Hypercholesterolemia","Secondary Prevention","2026-03-08",{"date":132,"type":38},"2026-03-10",{"date":134,"type":22},"2026-04",{"date":136,"type":22},"2026-10",{"name":138,"class":110},"Tor Biering-Sørensen",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":150,"conditions":151,"keywords":176,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":149,"type":22},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[152,153,154,155,156,157,158,159,160,161,162,163,164,165,30,166,167,168,169,170,171,172,173,174,175],"Kidney Transplant","Familial Hypercholesterolaemia","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Bone Marrow Transplant","Cancer (Solid Tumors)","Leukemia","Lymphoma","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[177,178,179],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":182,"type":38},"2025-08-08",{"date":184,"type":38},"2025-04-01",{"date":186,"type":22},"2029-01-31",{"name":188,"class":110},"Semmelweis University",3,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":111},"100592573","heart-ct-imaging-to-detect-early-coronary-artery-disease-in-first-degree-relatives-with-high-or-low-lipoproteina-identified-through-family-screening-100592573","NCT06995183","Heart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening","Improved Assessment of Cardiovascular Risk Through Imaging in Relatives Identified By Lipoprotein(a) Cascade Screening","IMAGE-LPA","In order to be eligible to participate in this study in the elevated Lp(a) subgroup, a subject must meet all of the following inclusion criteria:\n\n* Man or woman ≥50 years of age;\n* Lp(a) level ≥ 150 nmol\u002FL;\n* Identified as having elevated Lp(a) through Lp(a) family cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic;\n* Able and willing to provide informed consent;\n* Able to comply with study requirements.\n\nIn order to be eligible to participate in this study in the Low Lp(a) subgroup, a subject must meet all of the following inclusion criteria:\n\n* Man or woman ≥50 years of age;\n* Lp(a) level \\\u003C 50 nmol\u002FL;\n* Identified as having elevated Lp(a) through Lp(a) family cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic;\n* Able and willing to provide informed consent;\n* Able to comply with study requirements.\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study (both subgroups):\n\n* Renal insufficiency, defined as eGFR \\\u003C 30 ml\u002Fmin\n* History of ASCVD (acute coronary syndrome, history of myocardial infarction, stable or unstable angina pectoris or coronary or other arterial revascularization, stroke, transient ischemic attack or peripheral artery disease including aortic aneurysm, all of atherosclerotic origin)\n* History of atrial fibrillation\n* Prior and current use of statins\n* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator\n* Unable or unwilling to provide informed consent\n* Unable to comply with study requirements.","50 Years",{"count":200,"type":22},150,"Lipoprotein(a), or Lp(a), is a type of cholesterol that can increase the risk of heart and blood vessel disease. Many people are unaware they have high Lp(a), since it is not routinely measured and usually causes no symptoms on its own. However, elevated Lp(a) levels tend to run in families, meaning that close relatives of individuals with high Lp(a) are more likely to have it as well.\n\nAt Amsterdam UMC, family members of patients with high Lp(a) are invited for cascade screening, which includes testing for Lp(a) and other cardiovascular risk factors. From this screened group, a selection of individuals with either high or low Lp(a) levels are invited to participate in the IMAGE-LPA study.\n\nIn IMAGE-LPA, participants undergo a comprehensive cardiovascular evaluation, including blood tests and heart imaging using CT scans. Two types of scans are performed: (1) a calcium score scan to detect early calcium buildup in the heart's arteries (an early marker of atherosclerosis), and (2) coronary CT angiography to assess for plaque and narrowing in the coronary arteries.\n\nThe goal of the study is to compare individuals with high versus low Lp(a) identified through cascade screening, to determine whether high Lp(a) levels are associated with early signs of heart disease in this patient group.\n\nThe study does not involve any medications or invasive procedures. The findings may help clarify whether heart imaging can improve early detection in individuals with high Lp(a), and guide future strategies for preventing cardiovascular disease in families affected by this inherited risk factor.",[30],[30,204,205,206,207,208,209,210,211,212,213,214],"coronary atherosclerosis","subclinical atherosclerosis","coronary artery calcium scoring","coronary computed tomography angiography","cardiovascular risk assessment","primary prevention","coronary artery disease","cascade screening","imaging biomarkers","atherosclerotic cardiovascular disease","lipid disorders","2025-05-27",{"date":217,"type":38},"2025-05-29",{"date":219,"type":22},"2025-06",{"date":221,"type":22},"2026-12-31",{"name":223,"class":110},"E.S.stroes"]